Assess whether an OFAC match is true and requires blocking (8ec113)
August 31, 2026 · SmartSolo
Situation
Clinical-trial site anomaly report arrived with a SAR the institution filed late after a wire already left for IG improper-payments investigator. That is a US Federal AI Governance Vendor Risk decision on an OFAC match is in an IG shop scoping a whistleblower allegation.
Decision
IG improper-payments investigator in an IG shop scoping a whistleblower allegation must choose Pursue / Pursue with conditions / Partner / No-bid using clinical-trial site anomaly report after a SAR the institution filed late after a wire already left.
Hypotheses to test
- The population in clinical-trial site anomaly report is the one a SAR the institution filed late after a wire already left named, so Pursue follows for this AI Governance Vendor Risk file.
- The population in clinical-trial site anomaly report is adjacent only to a SAR the institution filed late after a wire already left; Pursue with conditions is the honest US Federal call.
- An IG shop scoping a whistleblower allegation already contained a SAR the institution filed late after a wire already left before clinical-trial site anomaly report arrived; no new AI Governance Vendor Risk path.
- Provenance on clinical-trial site anomaly report after a SAR the institution filed late after a wire already left is broken; do not pick Pursue or Pursue with conditions yet.
Analysis required
- Compare PTW and compliance gates in clinical-trial site anomaly report to a pursue / partner / no-bid split.
- Test OCI and SAM.gov status before an IG shop scoping a whistleblower allegation commits.
- Map FAR, Section L/M, and evaluator priorities in clinical-trial site anomaly report after a SAR the institution filed late after a wire already left.
- For this US Federal AI Governance Vendor Risk file, read clinical-trial site anomaly report against a SAR the institution filed late after a wire already left and write the one fact that would move an OFAC match is for IG improper-payments investigator.
Recommendation
Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / AI Governance Vendor Risk packet (clinical-trial site anomaly report after a SAR the institution filed late after a wire already left). The follow-on AI Governance Vendor Risk action is what IG improper-payments investigator does next: implement the option, assign an owner, and log the missing fact.
Explore more
More US Federal prompts
- Assess whether a trial site should be referred (279cfd)
- Assess whether intel indicators are prioritized for this network (b9625d)
- Assess whether threshold splitting is a procurement-integrity issue (123ed1)
- Assess whether SAR narratives show a real typology or copy-paste (1cf413)
- Assess whether the AI buy is high-risk and under-evaluated (453214)
Explore related decision areas
See governed multi-model AI on your own prompt
Compare GPT-5, Claude, and Gemini side by side, with human review and a decision record built in.

